You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The researchers said the findings underscore the need to study disease variants in a range of ancestral backgrounds.
The alliance, led by Singapore-based startup Proteona, also includes several organizations from that city state as well as German research institutes.
In Science this week: perspective piece says AI can accelerate drug discovery by using genomic and chemical data, and more.
For the first phase of the SG10K project, researchers sequenced thousands of Chinese, Malay, or Indian individuals from Singapore, uncovering new variants and population insights.
The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.
The company hopes to develop AI-based tools to improve the usefulness of its ESCAPE platform, which combines single-cell sequencing with protein analysis.
By comparing viruses in parts of China with or without endemic EBV-associated nasal cancers, researchers narrowed in on two viral variants associated with increased cancer risk.
The novel technology uses DNA-barcoded antibodies to enable single-cell RNA sequencing platforms to detect and quantify protein expression.
While the '3G' study did not establish clinical utility, the researchers said it shows genomic profiling to guide gastric cancer treatment is feasible.
Under the agreement, the researchers plan to sequence 150 AML genomes and transcriptomes to look for population-specific variants.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.